CFDE Data Portal | Search RPL13AP2

	Label	Description
	RPL13AP2 associations Collection (Entity type)	Associations for RPL13AP2_associations
	RPL13AP2 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	RPL13AP2 Gene (Entity type)	ENSG00000244053 - ribosomal protein L13a pseudogene 2
	GSE77108 saha 4 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115542 digoxin 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205714 GSE229013 adenosine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE192750 adipose overexpression Grunt Fin PNMR OE 5 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 0 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE214931 temozolomide 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119369 H10 inhibition 3 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS

RPL13AP2 associations

Associations for RPL13AP2_associations

RPL13AP2 associations.tsv

A file from IDG as part of the Harmonizome project

RPL13AP2

ENSG00000244053 - ribosomal protein L13a pseudogene 2

GSE77108 saha 4 v 7 human up

A Gene Set from LINCS

GSE115542 digoxin 2 v 0 human up

A Gene Set from LINCS

GSE205714 GSE229013 adenosine 3 v 2 human dn

A Gene Set from LINCS

GSE192750 adipose overexpression Grunt Fin PNMR OE 5 v 4 human dn

A Gene Set from LINCS

GSE261563 CX-5461 0 v 8 human dn

A Gene Set from LINCS

GSE214931 temozolomide 3 v 0 human dn

A Gene Set from LINCS

GSE119369 H10 inhibition 3 v 5 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.